6 results match your criteria: "Division of Gastroenterology and HepatologyMayo ClinicRochesterMNUSA.[Affiliation]"

Patients with decompensated cirrhosis, particularly those with acute-on-chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma metabolites of patients with decompensated cirrhosis, specifically on compounds characteristic of the ACLF plasma metabolomic profile. Two cohorts of patients were investigated.

View Article and Find Full Text PDF

Post-transplant diabetes mellitus (PTDM) is a significant contributor to morbidity and mortality in liver transplant recipients (LTRs). With concurrent comorbidities and use of various immunosuppression medications, identifying a safe and personalized regimen for management of PTDM is needed. There are many comorbidities associated with the post-transplant course including chronic kidney disease, cardiovascular disease, allograft steatosis, obesity, and de novo malignancy.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the roles of environmental chemicals and metabolic changes in the development of rare liver diseases, primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), as the current understanding of these aspects is limited.
  • - Using high-resolution mass spectrometry, researchers characterized various chemicals and metabolites in plasma, finding environmental agents linked to PSC and PBC, such as pesticides and pollutants.
  • - The research highlighted significant metabolic alterations related to these diseases and suggested a potential role for the 5-lipoxygenase pathway, laying a groundwork for better diagnostics and treatments.
View Article and Find Full Text PDF

Prostate-specific membrane antigen (PSMA) is a validated target for molecular diagnostics and targeted radionuclide therapy. Our purpose was to evaluate PSMA expression in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and hepatic adenoma (HCA); investigate the genetic pathways in HCC associated with PSMA expression; and evaluate HCC detection rate with Ga-PSMA-11 positron emission tomography (PET). In phase 1, PSMA immunohistochemistry (IHC) on HCC (n = 148), CCA (n = 111), and HCA (n = 78) was scored.

View Article and Find Full Text PDF

Hepatic fibrosis is driven by deposition of matrix proteins following liver injury. Hepatic stellate cells (HSCs) drive fibrogenesis, producing matrix proteins, including procollagen I, which matures into collagen I following secretion. Disrupting intracellular procollagen processing and trafficking causes endoplasmic reticulum stress and stress-induced HSC apoptosis and thus is an attractive antifibrotic strategy.

View Article and Find Full Text PDF

Cholangiocarcinoma (CCA) has poor prognosis due to late-stage, symptomatic presentation. Altered DNA methylation markers may improve diagnosis of CCA. Reduced-representation bisulfite sequencing was performed on DNA extracted from frozen CCA tissues and matched to adjacent benign biliary epithelia or liver parenchyma.

View Article and Find Full Text PDF